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ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN CHE-
MOTHERAPY REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Aljitawi, O.S., Krishnan, A., Nademanee, A., Palmer, J., Alvarnas, J.,
Cai, J.-L., Kirschbaum, M., Kogut, N., Nakamura, R., Popplewell, L.,
Sarkodee-Adoo, C., Schriber, J., Zain, J., Parker, P., Forman, S. City
of Hope Comprehensive Cancer Center, Duarte, CA.
Allogeneic HCT (Allo-HCT) is an effective treatment option for
CLL due to both cytoreductive therapy from the conditioning reg-
imen as well as the graft versus leukemia (GVL) effect. Tradition-
ally, chemosensitivity is a pre-requisite for Allo-HCT; however,
this may not be necessary in CLL due to the GVL effect. We iden-
tified a consecutive case-series of 29 patients who underwent an
Allo-HCT at the City of Hope Medical Center between1993 and
2006. The median age at transplantation was 48 years (38–68).
The median time from diagnosis to transplant was 49 months
(13–157). Median number of prior chemotherapy regimens was
3(1–6). Twenty four patients had prior fludarabine therapy and 10
were considered refractory. Sixteen patients received prior anthra-
cycline therapy. Twenty two patients had chemosensitive disease,
defined as $a partial response to salvage chemotherapy just prior
to Allo-HCT. The conditioning regimens used consisted of Fludar-
abine1Melphalan n 5 13, FTBI1Cytoxan n 5 11, Fludarabine1
Cytoxan1Rituximab n 5 1, FTBI1Etoposide n 5 1, FTBI1
Etoposide1Cytoxan n 5 1, Etposide1Cytoxan1BCNU n 5 1,
and Busulfan1Cytoxan n 5 1. Nine patients received an unrelated
donor graft and 20 received a sibling graft, including one patient
who received a syngeneic transplant. Thirteen patients received
a stem cell product derived from bone marrow, 16 from peripheral
blood. Graft versus host disease (GVHD) prophylaxis consisted
of cyclosporine-based regimen (n 5 22), Tacrolimus1Sirolimus
(n 5 3), Methotrexate1Tacrolimus (n 5 2), Methotrexate
1Methylprednisolone (n 5 1), and none in the syngeneic trans-
plant. The non-relapse mortality was 34% at five years. Five pa-
teints(17%) relapsed post Allo-HCT, 3 of them died of relapsed
disease. Ten patients(34%) developed grade 3–4 acute GVHD,
and 18(62%) developed chronic GVHD; 71% extensive. The me-
dian follow up for the 12 surviving patients is 67 months (9–163
months). The projected 5-year overall survival (OS) and disease-
free survival (DFS) rates for all patients were 59% (CI: 47–69)
and 48% (CI: 39–57) respectively. OS for the chemosensitive and
the chemorefractory patients were 71(CI: 54–82) and 29(CI:
20–38) (p 5 .07) respectively. The DFS, was 56(CI: 43–67) in the
chemosensitive patients and 29(CI: 20–38) in the chemorefractory
patients (p 5 .14).
Conclusion: Allo-HCT is effective and feasible in chemorefrac-
tory patients and offers disease free survival not significantly differ-
ent from patients with chemosensitive disease.294
PREDICTORS AND IMPACT OF DONOR T-CELL CHIMERISM IN MYELOA-
BLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
Dean, R.M.1, Sobecks, R.1, Rybicki, L.2, Brown, S.1, Copelan, E.1,
Kalaycio, M.1, Pohlman, B.1, Sweetenham, J.1, Andresen, S.1,
Bolwell, B.J.1. 1Cleveland Clinic Foundation, Cleveland, OH; 2Cleve-
land Clinic Foundation, Cleveland, OH.
Donor T-cell chimerism after myeloablative allogeneic stem cell
transplantation (alloSCT) has received little attention, perhaps be-
cause it is assumed to be less variable than after nonmyeloablative
alloSCT and thus less relevant. We studied the relationship of T-
cell subset chimerism to baseline parameters and transplantation
outcomes in patients (pts) undergoing myeloablative alloSCT at
the Cleveland Clinic Foundation from 9/2004 through 12/2006.
To minimize potential confounding effects of histocompatibility
upon engraftment and GVHD, this analysis was restricted to 59
pts (Table) who received 8/8 matched allografts at HLA-A, -B, -
C, and -DR. Median follow-up among 34 survivors is 20 months
(range, 5–35). Relapse (n 5 17) was the most common cause of
death (n 5 9), followed by acute (n 5 3) or chronic (n 5 6)
GVHD, and other causes (n 5 7). Grades II-IV acute GVHD oc-
curred in 26 pts (44%). Complete donor T-cell chimerism (CDC:at least 95% DNA of donor origin in peripheral blood CD31 T
cells by STR method) occurred in 52 pts overall, at a median 40
(range, 25–571) days after alloSCT. After CDC first occurred, it
was durable in 42 pts, of whom 25 survive. Mixed T-cell chimerism
(MC) recurred in 10 pts at median 54 (range, 12–318) days after first
achieving CDC. Of these, 5 pts recovered and maintained CDC,
and all survive. All 5 pts with persistent MC after prior CDC have
relapsed, and 4 have died. CDC was never attained in 7 pts, of
whom 4 have died. Among baseline and transplant characteristics,
both number of prior regimens (HR 1.30, 95% CI 1.02–1.65, P 5
0.03) and time from diagnosis to alloSCT (HR 1.31 per 6 month in-
crease, 95% CI 1.10–1.57, P 5 0.002) were associated with achiev-
ing CDC in univariable analysis, but only the latter parameter was
significant in multivariable models. No parameter predicted dura-
ble CDC.
Acute GVHD was more common among pts who achieved CDC
(HR 2.83, 95% CI 0.97–8.23, P 5 0.06). No association was ob-
served between chronic GVHD and CDC. However, durable
CDC appeared protective against relapse mortality (HR 0.23,
95% CI 0.06–0.90, P 5 0.04). Kaplan-Meier estimates of relapse-
free survival for pts with and without durable CDC were 60% versus
12% at 1 year post-alloSCT.
We conclude that measurement of T-cell chimerism provides
clinically relevant information about engraftment kinetics and
relapse risk, and may guide immunomodulatory maneuvers to en-
hance potential graft-versus-malignancy effects after myeloablative
alloSCT.Baseline and Transplant Characteristics
Variable Number (%)Donor
Related 33 (56%)
Unrelated 26 (44%)Age (years), median (range) 41 (19–62)
Diagnosis
AML 28 (47%)
ALL 16 (27%)
CML 6 (10%)
MDS 5 (8%)
NHL 2 (3%)
Aplastic anemia 2 (3%)Prior regimens, median
(range)2 (0–5)Disease status
Sensitive 38 (68%)
Refractory 18 (32%)Months from diagnosis to
alloSCT, median (range)5.5 (0.5–41)Preparative regimen
TBI-based 22 (37%)
Chemotherapy-based 37 (63%)Donor and recipient gender
F/F 17 (29%)
F/M 9 (15%)
M/F 18 (31%)
M/M 15 (25%)Graft type
BM 56 (95%)
PBSC 3 (5%)CD341 cells/kg recipient
weight, median (range)2.1  106 (0.33–8.44)CD31 cells/kg recipient
weight, median (range)33  106 (12–202)GVHD prophylaxis
CSA/MMF 30 (51%)
Tacro/MTX 23 (39%)
Tacro/MMF 4 (7%)
CSA/MTX 2 (3%)CSA, cyclosporine; MMF, mycophenolate; Tacro, tacrolimus;
MTX, methotrexate.
